Search Results

There are 3510 results for: content related to: Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study

  1. Rivastigmine for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline Birks, John Grimley Evans, Vasso Iakovidou and Magda Tsolaki

    Published Online : 15 APR 2009, DOI: 10.1002/14651858.CD001191.pub2

  2. Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease

    International Journal of Clinical Practice

    Volume 65, Issue 4, April 2011, Pages: 465–471, G. T. Grossberg, J. T. Olin, M. Somogyi and X. Meng

    Article first published online : 11 FEB 2011, DOI: 10.1111/j.1742-1241.2011.02641.x

  3. You have free access to this content
    Rivastigmine for vascular cognitive impairment

    Intervention Review

    The Cochrane Library

    Jacqueline Birks, Bernadette McGuinness and David Craig

    Published Online : 31 MAY 2013, DOI: 10.1002/14651858.CD004744.pub3

  4. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease

    Movement Disorders

    Volume 21, Issue 11, November 2006, Pages: 1899–1907, David Burn, Murat Emre, Ian McKeith, Peter Paul De Deyn, Dag Aarsland, Chuanchieh Hsu and Roger Lane

    Article first published online : 7 SEP 2006, DOI: 10.1002/mds.21077

  5. You have free access to this content
    CaMKII activity is essential for improvement of memory-related behaviors by chronic rivastigmine treatment

    Journal of Neurochemistry

    Volume 128, Issue 6, March 2014, Pages: 927–937, Shigeki Moriguchi, Hideaki Tagashira, Yuzuru Sasaki, Jay Z. Yeh, Hiroyuki Sakagami, Toshio Narahashi and Kohji Fukunaga

    Article first published online : 17 NOV 2013, DOI: 10.1111/jnc.12510

  6. Cholinesterase inhibitors for Alzheimer's disease

    Intervention Review

    The Cochrane Library

    Jacqueline Birks

    Published Online : 25 JAN 2006, DOI: 10.1002/14651858.CD005593

  7. Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 4, August 2010, Pages: 246–253, Murat Emre, Roberto Bernabei, Rafael Blesa, Roger Bullock, Luis Cunha, Hugo Daniëls, Edward Dziadulewicz, Hans Förstl, Lutz Frölich, Tomasz Gabryelewicz, Oleg Levin, James Lindesay, Pablo Martínez-Lage, Andreas Monsch, Magda Tsolaki and Teus Van Laar

    Article first published online : 29 MAR 2010, DOI: 10.1111/j.1755-5949.2010.00141.x

  8. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand

    Psychogeriatrics

    Volume 13, Issue 1, March 2013, Pages: 1–8, Kongkiat KULKANTRAKORN, Panas TANYAKITPISAL, Somchai TOWANABUT, Charungthai DEJTHEVAPORN, Poonsri RANGSEEKAJEE, Sunsanee PONGPAKDEE, Somsak LAPTIKULTHAM, Kritsada RODPRASERT, Suwanna SETTHAWATCHARAWANICH and Bandit THINKHAMROP

    Article first published online : 17 FEB 2012, DOI: 10.1111/j.1479-8301.2012.00403.x

  9. Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease

    International Journal of Clinical Practice

    G. Alva, J. L. Cummings, J. E. Galvin, X. Meng and D. M. Velting

    Article first published online : 16 FEB 2015, DOI: 10.1111/ijcp.12621

  10. Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch

    The Journal of Clinical Pharmacology

    Volume 49, Issue 4, April 2009, Pages: 430–443, Dr Gilbert Lefèvre, Ms Monika Büche, Dr Greg Sedek, Mr Steve Maton, Dr Albert Enz, Dr Ulrike Lorch, Dr Cyriaque Sagan and Dr Silke Appel-Dingemanse

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008330161

  11. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer’s disease

    International Journal of Clinical Practice

    Volume 64, Issue 5, April 2010, Pages: 651–660, G. T. Grossberg, C. Sadowsky and J. T. Olin

    Article first published online : 19 JAN 2010, DOI: 10.1111/j.1742-1241.2009.02330.x

  12. Pharmacokinetics and Bioavailability of the Novel Rivastigmine Transdermal Patch Versus Rivastigmine Oral Solution in Healthy Elderly Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 2, February 2008, Pages: 246–252, Dr Gilbert Lefèvre, Mrs Françoise Pommier, Dr Greg Sędek, Dr Mark Allison, Dr Hsun-Lun Aaron Huang, Mrs Beate Kiese, Dr Yu-Yun Ho and Dr Silke Appel-Dingemanse

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270007312154

  13. You have free access to this content
    A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule

    International Journal of Geriatric Psychiatry

    Volume 22, Issue 5, May 2007, Pages: 456–467, Bengt Winblad, Jeffrey Cummings, Niels Andreasen, George Grossberg, Marco Onofrj, Carl Sadowsky, Stefanie Zechner, Jennifer Nagel and Roger Lane

    Article first published online : 22 MAR 2007, DOI: 10.1002/gps.1788

  14. Cholinesterase inhibitors for Parkinson's disease dementia

    Intervention Review

    The Cochrane Library

    Ian Maidment, Chris Fox and Malaz Boustani

    Published Online : 25 JAN 2006, DOI: 10.1002/14651858.CD004747.pub2

  15. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment

    International Journal of Clinical Practice

    Volume 60, Issue 1, January 2006, Pages: 110–118, T. Dantoine, 1 S. Auriacombe, 2 M. Sarazin, 3 H. Becker, 4 J-J Pere and 5 I. Bourdeix 5

    Article first published online : 20 DEC 2005, DOI: 10.1111/j.1368-5031.2005.00769.x

  16. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy

    International Journal of Geriatric Psychiatry

    Volume 26, Issue 12, December 2011, Pages: 1236–1243, Martin R. Farlow, George T. Grossberg, Xiangyi Meng, Jason Olin and Monique Somogyi

    Article first published online : 23 DEC 2010, DOI: 10.1002/gps.2669

  17. Absorption of Rivastigmine from Different Regions of the Gastrointestinal Tract in Humans

    The Journal of Clinical Pharmacology

    Volume 44, Issue 6, June 2004, Pages: 599–604, Dr. Lucy Lee, Dr. Mohammad Hossain, Dr. Yanfeng Wang and Dr. Greg Sedek

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270004265645

  18. Efficacy of Rivastigmine on Executive Function in Patients with Parkinson's Disease Dementia

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 6, December 2010, Pages: 330–336, Frederick A. Schmitt, Martin R. Farlow, Xiangyi Meng, Sibel Tekin and Jason T. Olin

    Article first published online : 15 OCT 2010, DOI: 10.1111/j.1755-5949.2010.00182.x

  19. Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease

    ELECTROPHORESIS

    Volume 30, Issue 4, February 2009, Pages: 644–653, Ya-Hui Hsieh, Yuan-Han Yang, Hsin-Hua Yeh, Ping-Chih Lin and Su-Hwei Chen

    Article first published online : 23 JAN 2009, DOI: 10.1002/elps.200800559

  20. Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch

    CNS Neuroscience & Therapeutics

    Volume 16, Issue 1, February 2010, Pages: 51–60, C. Sadowsky, J.A. Davila Perez, R.W. Bouchard, I. Goodman and S. Tekin

    Article first published online : 8 JAN 2010, DOI: 10.1111/j.1755-5949.2009.00119.x